LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is advancing its first-in-class PP2A inhibitor, LB-100, and will participate in the DealFlow Discovery Conference to engage with investors [1][2]. Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, particularly targeting new cancer drug development [2]. - The lead compound, LB-100, has shown to be well-tolerated in cancer patients and has the potential to enhance chemotherapies and immunotherapies [2][3]. Product Development - LB-100 is part of a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [3]. - LIXTE has a comprehensive patent portfolio covering its innovative approach to cancer treatment [3]. Subsidiary Operations - Through its subsidiary, Liora Technologies Europe Ltd., LIXTE is developing electronically controlled proton therapy systems, specifically the LiGHT System, which is expected to offer significant advantages over existing proton therapy technologies [4].